CMPS

COMPASS Pathways plc

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

COMPASS PathwaysLONDON, Aug. 04, 2022 --Highlights:Kabir Nath appointed as Chief Executive Officer Phase III program submitted to FDA and under reviewCOMP360 phase II study in anorexia nervosa launchedCash position at 30 June 2022 of $207.2 millionConference call today at 8:00am ET (1:00pm UK)COMPASS Pathways plc (Nasdaq: CMPS) (β€œCOMPASS”... Read More...

COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022

COMPASS PathwaysLONDON, July 26, 2022 -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2022, and provide an update on recent business developments on 4 Au... Read More...

COMPASS Pathways plc to announce first quarter 2022 financial results on 10 May 2022

COMPASS PathwaysLONDON, May 03, 2022 -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2022, and provide an update on recent business developments on 10 May... Read More...

COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

Highlights:Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021Partnership being developed with leading UK institutions to accelerate psychedelic research and develop new models of mental health care in the UKGuy Goodwin appointed Chief Medical Offi... Read More...

COMPASS Pathways plc to announce second quarter 2021 financial results on 11 August 2021

London, UK, Aug. 04, 2021 -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2021, and provide an update on recent business developments, on 11 August 2021.... Read More...

COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers

LONDON, June 03, 2021 -- COMPASS Pathways plc (Nasdaq: CMPS) (β€œCOMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive functio... Read More...